Hearscape
Therapies database

Find a therapy. Follow the evidence.

See what is being studies, who is developing it, and how far it has progressed.

Search therapy records

Search a therapy, company, target, indication, or trial ID. Narrow by approach, stage, or status, then open a record to check its sources.

More filters and sort (1 active)
4 results
Otarmeni by Regeneron
Regeneron Pharmaceuticals · Gene Therapy · Approved
ApprovedTherapeuticStronger sources
Population
Children & adults · FDA label has no age bounds; trial: 10 months–16 years
Biallelic OTOF severe-to-profound deafness
Evidence
regulatory
Confidence
99%
Indications
Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss
Details
AK-OTOF by Eli Lilly and Akouos
Eli Lilly and Company · Gene Therapy · Phase 2
ActiveTherapeuticStronger sources
Population
Children & adults · Cohort-specific; no overall age limit
Biallelic OTOF profound bilateral auditory neuropathy
Evidence
trial
Confidence
95%
Indications
Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss
Details
SENS-501 by Sensorion
Sensorion · Gene Therapy · Phase 1/2
ActiveTherapeuticStronger sources
Population
Children · 6–31 months
Biallelic OTOF deafness with preserved outer-hair-cell function
Evidence
trial
Confidence
94%
Indications
Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss
Details
EHT102 by EuHearing
Shanghai EuHearing Therapeutics Co., Ltd · Gene Therapy · Phase 1/2
ActiveTherapeutic
Population
Children · 1–17 years
Biallelic OTOF DFNB9 severe-to-profound deafness
Evidence
trial
Confidence
90%
Indications
Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss
Details

A listing is not proof of safety or effectiveness. Approval and availability may vary by indication and country.

How records are checked